Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring
Review
[키워드] acute respiratory distress
added
adjusted
Anticoagulant
Anticoagulant treatment
ARDS
body mass index
changes
characterized
Coagulation
coronavirus
COVID-19
criteria
curative
D-dimer
D-dimer levels
defined
Diagnosis
dialysis
dose
ECMO
extracorporeal membrane oxygenation
fibrinogen
Fibrinogen levels
form
Hemostasis
heparin
higher risk
hospitalized patient
hypercoagulability
ICU
ICU Patients
increase in
Infection
Inflammation
Inflammatory
intensive care
intermediate dose
LMWH
low molecular weight
management
monitoring
obese patient
obesity
Oxygen requirement
prevention
Prophylaxis
reflected
renal
risk factor
Risk factors
severe COVID-19
severity
severity of COVID-19
Standard
Standard dose
syndrome
the SARS-CoV-2
therapeutic dose
thromboembolic risk
Thromboembolism
thrombosis
thrombotic risk
Treatment
unfractionated heparin
ventilated patients
with COVID-19
[DOI] 10.1186/s13054-020-03000-7 PMC 바로가기 [Article Type] Review
[DOI] 10.1186/s13054-020-03000-7 PMC 바로가기 [Article Type] Review